How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics

Aug 26, 2016, 07:50 ET from Chelmsford Park SA

NEW YORK, August 26, 2016 /PRNewswire/ -- has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:

Progenics Pharma  

On Thursday, shares in Tarrytown, New York-based Progenics Pharmaceuticals Inc. recorded a trading volume of 1.48 million shares. The stock ended the session 0.61% lower at $6.52. The Company's shares have gained 7.59% in the last one month, 36.69% in the previous three months, and 6.36% on an YTD basis. The stock is trading 16.37% above its 50-day moving average and 24.90% above its 200-day moving average. Moreover, shares of Progenics Pharmaceuticals, which develops medicines for oncology in the US and internationally, have a Relative Strength Index (RSI) of 57.05.

On August 4th, 2016, Progenics Pharmaceuticals announced that net loss attributable to the company for Q2 2016 was $5.6 million, or $0.08 per diluted share, compared to a net loss of $11.7 million, or $0.17 per diluted share, in Q2 2015. Progenics ended the quarter with cash and cash equivalents of $60.1 million, a decrease of $5.5 million in the quarter. The company's Q2 2016 revenue totaled $8.5 million, up from $1.9 million in Q2 2015, reflecting RELISTOR royalty income of $2.4 million compared to $1.8 million in the 2015 period, based on net sales reported to Progenics by Valeant. Access our complete research report on PGNX for free at:

Peregrine Pharma  

Tustin, California headquartered Peregrine Pharmaceuticals Inc.'s stock closed the day 2.70% lower at $0.36 and with a total volume of 369,252 shares traded. Shares of the Company, which researches and develops monoclonal antibodies for the treatment of cancer in the US, are trading 5.66% below their 50-day moving average. The stock has an RSI of 46.47. The complimentary research report on PPHM can be downloaded at:

Agios Pharma  

Shares in Cambridge, Massachusetts-based Agios Pharmaceuticals Inc. recorded a trading volume of 914,352 shares, which was higher than their three months average volume of 722,970 shares. The stock ended yesterday's trading session 1.14% lower at $38.08. The Company's shares are trading below their 50-day moving average by 11.63%. Furthermore, shares of Agios Pharmaceuticals, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, have an RSI of 36.96.

On August 16th, 2016, Agios Pharmaceuticals announced that Andrew Hirsch is joining the company as chief financial officer, effective September 19th, 2016. Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, most recently having served as president and chief executive officer of BIND Therapeutics. Register for free on and get access to the latest PDF format report on AGIO at:

Cara Therapeutics  

Shelton, Connecticut headquartered Cara Therapeutics Inc.'s stock finished Thursday's session 1.08% lower at $5.50 with a total volume of 660,318 shares traded. Shares of the Company, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, are trading above their 50-day moving average by 0.17%. The stock has an RSI of 43.99.

On August 5th, 2016, Cara Therapeutics reported a net loss of $13.1 million, or $0.48 per basic and diluted share, for Q2 2016 compared to a net loss of $5.7 million, or $0.25 per basic and diluted share, for Q2 2015. The company recognized $79,000 of clinical compound revenue in Q2 2016 from the sale of clinical compound to Maruishi Pharmaceutical Company Ltd. For Q2 2015, collaborative revenue was $874,000, comprising revenue that had been deferred upon entry into the license agreement with Maruishi. As of June 30, 2016, cash and cash equivalents and marketable securities totaled $84.8 million compared to $106.7 million at December 31, 2015.

On August 08th, 2016, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $27 a share to $23 a share. Download your free research report on CARA at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA